The Motley Fool identified four issues that contributed to the decrease.
1. In the fourth quarter of fiscal year 2016:
- Valeant’s Branded Rx drug segment saw its sales drop 17 percent.
- Revenues from its Bausch & Lomb operation dropped 1 percent.
- Valeant set an EBITDA between $3.55 billion to $3.7 billion, which was approximately two times more than what it will pay in interest on its debt. Motley Fool said, “That’s worrisomely low.”
2. Valeant completed a series of refinancing deals. Although the refinancing pushes back its debt schedule, it adds fees or a higher interest rate.
3. Longtime Valeant supporter and hedge fund manager Bill Ackman sold his entire state in the company. Mr. Ackman lost approximately $4 billion from the investment.
4. Former CEO J. Michael Pearson announced that he was suing Valeant over unpaid compensation.
The Motley Fool said there’s no simple fix to Valeant’s issues. It recommends avoiding the stock.
https://www.beckersasc.com/gastroenterology-and-endoscopy/valeant-s-former-ceo-suing-drugmaker-over-3m-withheld-shares-6-insights.html
More articles on gastroenterology:
Missouri health system names gastroenterologist Dr. Kevin Byrne ‘Physician of the Year’: 4 key notes
GI leader to know: Dr. Amy Oxentenko of Mayo Clinic
CMS adds Cologuard to Medicare Advantage Star Ratings program: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.